Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir

In an exclusive interview, Niagen Bioscience’s (NAGE) CFO Ozan Pamir met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more.

LEADER IN NAD+: Niagen Bioscience, formerly ChromaDex Corp, is a leader in NAD+, or nicotinamide adenine dinucleotide, science and healthy-aging research. As a pioneer of NAD+ discoveries, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

“NAD is a coenzyme that exists in every living cell of every living being that is crucial to the metabolic function and the mitochondrial function of the cell. And this coenzyme declines as you age. What happens is that your cells lose the ability to heal themselves once the NAD levels decline and that’s the main cause of aging. accumulation of damage. You need to be able to elevate NAD levels in yourselves, in your tissues in order to improve your health and maintain healthy aging. One way to do that is by taking our product, True Nigen — which is a precursor to NAD. We have been selling this as a direct consumer product for the last 8 years. And we also sell it as an ingredient to different companies that are interested in improving their customers’ health,” CFO Ozan Pamir explained to The Fly.

“Over the last year, we have launched an IV product, using our precursor, an NAD percursor, Niagen IV. This Nigen IV is a direct competitor to the NAD IV that you may see on the market, but it is a significantly superior product. The company also has a strategy to enter the pharmaceutical space. We have a portfolio of other NAD precursors that are very effective at elevating NAD levels and alleviating some of the disease symptoms.”

NAD MARKET: Discussing the NAD+-related market, Pamir told The Fly that Niagen is “the only company, in the NAD space that is credible and legitimate.” “There are other companies who sell NAD as a molecule, which is a large molecule that cannot enter the cell; it actually causes more harm than good. And there are some other precursors out there that are inferior to Niagen. We have a very good sense of what the market should be. Every single human being should be taking Niagen because NAD is a coenzyme that exists in every cell of every living being, and it declines as the age. And because of that, the total addressable market is incredibly big. We do see ourselves as a fast growth consumer healthcare company. However, there are some caveats. We are not a company that’s now growing 500% every year. We are very, very conservative in how we run the business. We’re very methodical in where we allocate our capital. We are very much focused on profitability. So, while we are growing fast, we value the financial health of our company as well.”

CLINICAL TRIALS: Niagen has developed an external research program, with about 40 clinical trials done to date. “They vary in different indications,” the executive explained. “Some of them are focused on heart disease, some of them are focused on neurodegenerative, and some of them are for overall aging.” The company is currently focusing on two diseases. “One of them is a rare disease called Ataxia-Telangiectasia and the 2nd one is Parkinson’s Disease.”

MILESTONES: Looking out over the remainder of the year, Niagen’s CFO highlights the upcoming earnings release, scheduled for the beginning of November. “That’s the first milestone we are working towards. Following that, we plan to launch an at home injection kit, with our own telehealth capability. Then there are Parkinson’s results that I expect will be out in early 2026.”

MISCONCEPTIONS: Discussing any potential misconceptions about the company, Niagen’s CFO tells The fly that he believes there’s a consumer misconception about NAD itself. “People think that they will be able to elevate NAD levels by taking NAD. But that’s not how it works. NAD is a large molecule and cannot enter the cell. You need to take a precursor to NAD and the most efficient precursor to NAD is Niagen. That’s an education that we, as a company, are constantly working on.”

“From an investor standpoint, it is very hard to put our company into a bucket. We’re not just another supplement company. We are very much focused on our profitability, while, also maintaining healthy growth levels. You look at comparables in the supplement industry, and it’s not really ‘apples to apples.’ We have significant patent protection around our molecule, and we have done a great job commercializing that molecule. The right way to value the company may be to look at a sum-of-the-parts analysis, because of the different verticals we operate in,” the executive added.

Meet the Company” is The Fly’s recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.